Decibel Therapeutics Competitors and Similar CompaniesClear all
ElectroCore's competitors and similar companies include HDL Therapeutics and ReShape Lifesciences.
 ElectroCore ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders. |  HDL Therapeutics HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis. |  ReShape Lifesciences ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. | |
Founding Date | Founding Date 2005 | Founding Date 2009 | Founding Date 2002 |
Type | Type Public | Type Private | Type Public |
Tags | |||
Locations | Locations Rockaway, US HQ Parksville, CA Geretsried, DE Hamburg, DE Yeadon, GB Bernards, US | Locations Vero Beach, US HQ | Locations San Clemente, US HQ San Clemente, US |
Employees | Employees 5144% decrease | Employees 7 | Employees 4348% decrease |
Valuation ($) | Valuation ($) 71.2 m | Valuation ($) N/A | Valuation ($) 3 m |
Financial | |||
Revenue (est.) | Revenue (est.) $32m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $11.3m (FY, 2020) |
Cost of goods | Cost of goods $4.2m (FY, 2025) | Cost of goods N/A | Cost of goods $5m (FY, 2020) |
Gross profit | Gross profit $27.8m (FY, 2025) | Gross profit N/A | Gross profit $6.3m (FY, 2020) |
Net income | Net income ($14m) (FY, 2025) | Net income N/A | Net income ($21.6m) (FY, 2020) |
Funding | |||
Total funding raised | Total funding raised $ 127m | Total funding raised $ 7.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
HDL Therapeutics
HQ
Vero Beach, US
Employees
7
HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis.
View companyReShape Lifesciences
HQ
San Clemente, US
Employees
43↓ 48% decrease
ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.
View company